Canada’s Bold Opportunity to Lead the Fight Against HIV

Canada stands at a pivotal crossroads in its battle against HIV. With scientific advancements like Treatment as Prevention (TasP) and pre-exposure prophylaxis (PrEP), combined with global strategies like the 90-90-90 initiative, the tools to end new HIV infections are within reach. Yet, while the potential for leadership is enormous, progress has been uneven. Provinces like British Columbia have made strides, but systemic gaps persist across the nation.

The 90-90-90 strategy—a visionary roadmap endorsed by the World Health Organization (WHO)—aims to ensure 90% of people living with HIV know their status, 90% of those diagnosed receive treatment, and 90% achieve viral suppression. This approach is proven to save lives and curb transmissions, yet Canada’s commitment to implementing it has been inconsistent. If Canada embraces this strategy with the necessary urgency, it could become a global model for tackling the HIV epidemic.

Dr. Julio Montaner, a pioneer in HIV research and Director of the BC Centre for Excellence in HIV/AIDS, has long championed TasP and 90-90-90. His leadership has propelled British Columbia to the forefront of HIV prevention and treatment. But as the national conversation unfolds, Montaner emphasizes that federal action and collaboration are critical to achieving success across all provinces.

TasP and the Promise of the 90-90-90 Strategy

The foundation of the 90-90-90 strategy lies in addressing the HIV care continuum. The first step—diagnosing 90% of people living with HIV—requires widespread, accessible testing. The second, ensuring treatment for 90% of those diagnosed, demands removing barriers like cost and stigma. Finally, achieving viral suppression for 90% of those treated underscores the need for sustained support and education.

British Columbia’s success with TasP demonstrates how this strategy works. By prioritizing early diagnosis and immediate treatment, the province has reduced new HIV diagnoses and improved quality of life for those living with the virus. TasP’s core message, “Undetectable equals Untransmittable” (U=U), has been a game-changer, proving that individuals with undetectable viral loads cannot transmit HIV. However, scaling this model across Canada requires significant investment and political will.

PrEP: A Transformative Tool for Prevention

Pre-exposure prophylaxis (PrEP) has emerged as a vital tool in preventing HIV. A daily pill, PrEP reduces the risk of HIV transmission by up to 99% when taken consistently. Cities like San Francisco have demonstrated its effectiveness, with PrEP adoption contributing to a significant decline in new HIV infections.

In Canada, however, access to PrEP remains uneven. Unlike British Columbia, where some coverage exists, many provinces lack universal programs, leaving high-risk populations—such as men who have sex with men (MSM)—unable to afford this life-saving medication. Expanding PrEP access through provincial health plans and raising awareness are crucial steps in reducing transmission rates nationwide.

The Role of Stigma and Legal Barriers

Scientific advancements alone cannot end the HIV epidemic; tackling stigma and outdated laws is equally important. A 2012 survey found that 29% of Canadians held medium or high levels of stigma toward people living with HIV, a figure unchanged since 2006. This stigma discourages testing and treatment, creating barriers to achieving the 90-90-90 goals.

Canada’s legal framework exacerbates these challenges. Laws criminalizing HIV non-disclosure and exposure are inconsistent with public health objectives, discouraging openness and testing. Additionally, the criminalization of sex work and substance use disproportionately affects marginalized communities, further hindering access to care. Comprehensive legal reforms are essential to fostering an environment where TasP and PrEP can reach their full potential.

Lessons from British Columbia

British Columbia has become a shining example of what’s possible when public health priorities are aligned with science. Under Dr. Montaner’s leadership, the province implemented TasP as a cornerstone of its HIV strategy, offering free testing and antiretroviral therapy to those diagnosed. The results speak for themselves: a significant reduction in new HIV diagnoses and improved health outcomes for people living with HIV.

What sets British Columbia apart is its emphasis on accessibility and harm reduction. For example, injection drug users, a group historically at high risk for HIV, have benefited from harm reduction initiatives like safe injection sites and needle exchange programs. These efforts, combined with TasP, have led to a dramatic decline in new infections among this population.

Yet, as Dr. Montaner points out, the MSM community has not seen the same degree of progress. Sexual transmission networks present unique challenges, requiring targeted strategies and widespread education to complement medical interventions.

The Importance of Testing and Early Treatment

Routine HIV testing is the cornerstone of prevention and care. Dr. Montaner advocates for widespread, accessible testing for all adolescents and adults, with more frequent testing for high-risk groups. Early diagnosis not only improves health outcomes for individuals but also reduces the likelihood of further transmission.

Despite this, testing remains inconsistent across Canada, with rural and Indigenous communities particularly underserved. Expanding free and confidential testing services is essential to closing these gaps. Federal leadership is needed to support provinces in prioritizing HIV testing and treatment programs as part of a unified national strategy.

Expanding Access to Care

One of the key barriers to achieving the 90-90-90 targets is the cost of care. Co-payments, deductibles, and other financial hurdles deter many individuals from accessing treatment. Dr. Montaner stresses the importance of offering free or heavily subsidized services, pointing to British Columbia’s model as an example to emulate.

Equally important is ensuring culturally competent care for marginalized populations. MSM, transgender individuals, sex workers, and people who use drugs often face discrimination within the healthcare system. Addressing these inequities requires targeted training for healthcare providers and investments in community-based services.

The Road Ahead: Canada’s Role in Global Leadership

Canada has an opportunity to set a global example by embracing the 90-90-90 strategy, expanding PrEP access, and addressing systemic barriers. Federal support is crucial, particularly in revising the National AIDS Strategy to reflect modern advancements and priorities. By working collaboratively with provinces, healthcare providers, and community organizations, Canada can ensure that no one is left behind.

Leadership also means contributing to global efforts. Dr. Montaner has played a key role in shaping international HIV policy, and Canada has the expertise to support countries with fewer resources. Balancing domestic and global priorities will be essential as the fight against HIV continues.

A Brighter Future for HIV Prevention

The tools to end the HIV epidemic exist, but implementing them requires bold action and unwavering commitment. From expanding TasP and PrEP to dismantling stigma and legal barriers, Canada has the potential to lead the way. By embracing evidence-based strategies and prioritizing equity, the country can take a significant step toward a future free from HIV.

What are your thoughts on Canada’s role in HIV prevention? Have you experienced the benefits of TasP or PrEP? Share your insights, ideas, and experiences in the comments below.